{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:07Z","timestamp":1791999427851,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-022-08944-y","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T08:04:05Z","timestamp":1653033845000},"page":"330-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis"],"prefix":"10.1007","volume":"63","author":[{"given":"David F.","family":"Fiorentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4172-1539","authenticated-orcid":false,"given":"Livia","family":"Casciola-Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"issue":"6167","key":"8944_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1126\/science.1246886","volume":"343","author":"CG Joseph","year":"2014","unstructured":"Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152\u2013157","journal-title":"Science"},{"issue":"6","key":"8944_CR2","first-page":"1048","volume":"37","author":"DF Fiorentino","year":"2019","unstructured":"Fiorentino DF, Gutierrez-Alamillo L, Hines D, Yang Q, Casciola-Rosen L (2019) Distinct dermatomyositis populations are detected with different autoantibody assay platforms. Clin Exp Rheumatol 37(6):1048\u20131051","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"8944_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","volume":"52","author":"M Bonifazi","year":"2013","unstructured":"Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A (2013) Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 52(1):143\u2013154","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"8944_CR4","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/art.37969","volume":"65","author":"A Onishi","year":"2013","unstructured":"Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65(7):1913\u20131921","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8944_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/BOR.0000000000000755","volume":"32","author":"K Morrisroe","year":"2020","unstructured":"Morrisroe K, Nikpour M (2020) Cancer and scleroderma: recent insights. Curr Opin Rheumatol 32(6):479\u2013487","journal-title":"Curr Opin Rheumatol"},{"key":"8944_CR6","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.3389\/fimmu.2018.03112","volume":"9","author":"ATJ Maria","year":"2018","unstructured":"Maria ATJ, Partouche L, Goulabchand R, Riviere S, Rozier P, Bourgier C, Le Quellec A, Morel J, Noel D, Guilpain P (2018) Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors. Front Immunol 9:3112","journal-title":"Front Immunol"},{"issue":"2","key":"8944_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/art.38928","volume":"67","author":"AA Shah","year":"2015","unstructured":"Shah AA, Casciola-Rosen L, Rosen A (2015) Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 67(2):317\u2013326","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"8944_CR8","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar4486","volume":"16","author":"P Moinzadeh","year":"2014","unstructured":"Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16(1):R53","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"8944_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.autrev.2013.09.006","volume":"13","author":"M Colaci","year":"2014","unstructured":"Colaci M, Giuggioli D, Vacchi C, Lumetti F, Iachetta F, Marcheselli L, Federico M, Ferri C (2014) Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev 13(2):132\u2013137","journal-title":"Autoimmun Rev"},{"issue":"9","key":"8944_CR10","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/art.27549","volume":"62","author":"AA Shah","year":"2010","unstructured":"Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies. Arthritis Rheum 62(9):2787\u20132795","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8944_CR11","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1186\/ar3544","volume":"13","author":"M Nikpour","year":"2011","unstructured":"Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W (2011) Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 13(6):R211","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"8944_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3899\/jrheum.101144","volume":"38","author":"P Airo","year":"2011","unstructured":"Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F (2011) Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38(7):1329\u20131334","journal-title":"J Rheumatol"},{"issue":"7","key":"8944_CR13","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1111\/1346-8138.15383","volume":"47","author":"N Aozasa","year":"2020","unstructured":"Aozasa N, Miyazaki M, Hayakawa J, Tamaki T, Hamaguchi Y, Sato S, Asano Y (2020) Case of systemic sclerosis with multiple primary malignancies in whom anti-RNA polymerase III antibody was detected by immunoprecipitation. J Dermatol 47(7):e269\u2013e270","journal-title":"J Dermatol"},{"issue":"47","key":"8944_CR14","doi-asserted-by":"publisher","first-page":"E7526","DOI":"10.1073\/pnas.1615990113","volume":"113","author":"GJ Xu","year":"2016","unstructured":"Xu GJ, Shah AA, Li MZ, Xu Q, Rosen A, Casciola-Rosen L, Elledge SJ (2016) Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci USA 113(47):E7526\u2013E7534","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"8944_CR15","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/art.40065","volume":"69","author":"AA Shah","year":"2017","unstructured":"Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ, Casciola-Rosen L (2017) Brief report: anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma. Arthritis Rheumatol 69(6):1306\u20131312","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 106","key":"8944_CR16","first-page":"71","volume":"35","author":"AA Shah","year":"2017","unstructured":"Shah AA, Rosen A, Hummers LK, May BJ, Kaushiva A, Roden RBS, Armstrong DK, Wigley FM, Casciola-Rosen L, Visvanathan K (2017) Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clin Exp Rheumatol 35(Suppl 106):71\u201374","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"8944_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13075-018-1678-9","volume":"20","author":"ZE Betteridge","year":"2018","unstructured":"Betteridge ZE, Priest L, Cooper RG, McHugh NJ, Blackhall F, Lamb JA (2018) Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. Arthritis Res Ther 20(1):176","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"8944_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/jcm9030853","volume":"9","author":"L Partouche","year":"2020","unstructured":"Partouche L, Goulabchand R, Maria ATJ, Riviere S, Jorgensen C, Rigau V, Bourgier C, Bessis D, Le Quellec A, Quere I, Morel J, Guilpain P (2020) Biphasic temporal relationship between cancers and systemic sclerosis: a clinical series from Montpellier University Hospital and review of the literature. J Clin Med 9(3):853","journal-title":"J Clin Med"},{"issue":"9","key":"8944_CR19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.40893","volume":"71","author":"AA Shah","year":"2019","unstructured":"Shah AA, Laiho M, Rosen A, Casciola-Rosen L (2019) Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma. Arthritis Rheumatol 71(9):1571\u20131579","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"8944_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/BOR.0b013e32834a5081","volume":"23","author":"AA Shah","year":"2011","unstructured":"Shah AA, Rosen A (2011) Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 23(6):530\u2013535","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"8944_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.41493","volume":"73","author":"CA Mecoli","year":"2021","unstructured":"Mecoli CA, Adler BL, Yang Q, Hummers LK, Rosen A, Casciola-Rosen L, Shah AA (2021) Cancer in systemic sclerosis: analysis of antibodies against components of the Th\/To complex. Arthritis Rheumatol 73(2):315\u2013323","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"8944_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1588084","volume":"8","author":"A Watad","year":"2019","unstructured":"Watad A, McGonagle D, Bragazzi NL, Tiosano S, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H (2019) Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. Oncoimmunology 8(6):e1588084","journal-title":"Oncoimmunology"},{"issue":"4","key":"8944_CR23","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.39022","volume":"67","author":"AA Shah","year":"2015","unstructured":"Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM (2015) Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol 67(4):1053\u20131061","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"8944_CR24","first-page":"1179","volume":"77","author":"T Igusa","year":"2018","unstructured":"Igusa T, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L, Rosen A, Shah AA (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77(8):1179\u20131186","journal-title":"Ann Rheum Dis"},{"key":"8944_CR25","first-page":"489","volume":"53","author":"G Stertz","year":"1916","unstructured":"Stertz G (1916) Polymyositis. Berl Klin Wochenschr 53:489","journal-title":"Berl Klin Wochenschr"},{"key":"8944_CR26","first-page":"335","volume":"120","author":"H Kankeleit","year":"1916","unstructured":"Kankeleit H (1916) \u00dcber primaire nichteitrige polymyositis. Dtsch Arch Klin Med 120:335\u2013339","journal-title":"Dtsch Arch Klin Med"},{"issue":"7","key":"8944_CR27","first-page":"1300","volume":"22","author":"A Airio","year":"1995","unstructured":"Airio A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22(7):1300\u20131303","journal-title":"J Rheumatol"},{"issue":"1","key":"8944_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00051675","volume":"6","author":"WH Chow","year":"1995","unstructured":"Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6(1):9\u201313","journal-title":"Cancer Causes Control"},{"issue":"6","key":"8944_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJM199202063260602","volume":"326","author":"B Sigurgeirsson","year":"1992","unstructured":"Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis: A population-based study. N Engl J Med 326(6):363\u2013367","journal-title":"N Engl J Med"},{"issue":"9250","key":"8944_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96\u2013100","journal-title":"Lancet"},{"issue":"2","key":"8944_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1203475416665601","volume":"21","author":"JK Qiang","year":"2017","unstructured":"Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 21(2):131\u2013136","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"8944_CR32","first-page":"525","volume":"149","author":"D Di Rollo","year":"2014","unstructured":"Di Rollo D, Abeni D, Tracanna M, Capo A, Amerio P (2014) Cancer risk in dermatomyositis: a systematic review of the literature. G Ital Dermatol Venereol 149(5):525\u2013537","journal-title":"G Ital Dermatol Venereol"},{"issue":"4","key":"8944_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2230.2009.03216.x","volume":"34","author":"V Madan","year":"2009","unstructured":"Madan V, Chinoy H, Griffiths CE, Cooper RG (2009) Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 34(4):451\u2013455","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"8944_CR34","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70(6):360\u2013374","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"8944_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1084\/jem.20041367","volume":"201","author":"L Casciola-Rosen","year":"2005","unstructured":"Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591\u2013601","journal-title":"J Exp Med"},{"issue":"1","key":"8944_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","volume":"46","author":"K Kaji","year":"2007","unstructured":"Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 46(1):25\u201328","journal-title":"Rheumatology"},{"issue":"11","key":"8944_CR37","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1002\/art.22164","volume":"54","author":"IN Targoff","year":"2006","unstructured":"Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O\u2019Hanlon TP, Miller FW, Rider LG (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682\u20133689","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8944_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K (2012) Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64(2):513\u2013522","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8944_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2340\/00015555-3091","volume":"99","author":"M Best","year":"2019","unstructured":"Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D (2019) Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol 99(3):256\u2013262","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"8944_CR40","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/key357","volume":"58","author":"A Oldroyd","year":"2019","unstructured":"Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper RG, Chinoy H, UkmyoNet (2019) The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford) 58(4):650\u2013655","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"8944_CR41","first-page":"990","volume":"36","author":"M Ogawa-Momohara","year":"2018","unstructured":"Ogawa-Momohara M, Muro Y, Mitsuma T, Katayama M, Yanaba K, Nara M, Kakeda M, Kono M, Akiyama M (2018) Strong correlation between cancer progression and anti-transcription intermediary factor 1gamma antibodies in dermatomyositis patients. Clin Exp Rheumatol 36(6):990\u2013995","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"8944_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","volume":"19","author":"H Yang","year":"2017","unstructured":"Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, Lu X, Shu X, Zhang S, Wang G (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"8944_CR43","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL (2017) Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 69(11):1771\u20131776","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8944_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K, Nagy-Vincze M, Bodoki L, Dastmalchi M, Ekholm L, Lundberg IE, McHugh N, contributors UK (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48\u201355","journal-title":"J Autoimmun"},{"issue":"6","key":"8944_CR45","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.jaad.2020.03.058","volume":"83","author":"G Monseau","year":"2020","unstructured":"Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, Martel C, Masseau A, Meyer A, Terrier B, Guegan S, Verneuil L, Audia S, Livideanu CB, Hachulla E, Kahn JE, Lefevre G, Maurier F, Moulis G, Papo T, Dossier A, Descamps V, Salort-Campana E, Richard MA, Bergot E, Mortier L, Costedoat-Chalumeau N, Genot S, Perez F, Piette AM, Samson M, Schleinitz N, Zenone T, Lacoste M, de Boysson H, Madaule S, Rigolet A, Champtiaux N, Hervier B, Bouvier AM, Jooste V, Leonard-Louis S, Maisonobe T, Aouba A, Benveniste O, Bienvenu B, Allenbach Y, French Myositis N (2020) Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol 83(6):1759\u20131763","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"8944_CR46","first-page":"1191","volume":"38","author":"YM Zhang","year":"2020","unstructured":"Zhang YM, Liang L, Yang HB, Shu XM, Lu X, Wang GC, Peng QL (2020) Identification of a novel autoantibody against heat shock factor 1 in idiopathic inflammatory myopathy. Clin Exp Rheumatol 38(6):1191\u20131200","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"8944_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1195","volume":"9","author":"H Chen","year":"2020","unstructured":"Chen H, Yang H, Cheng QX, Ge YP, Peng QL, Zhang YM, Cheng GH, Wang GC, Lu X (2020) A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies. Clin Transl Immunology 9(10):e1195","journal-title":"Clin Transl Immunology"},{"issue":"12","key":"8944_CR48","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/1346-8138.15526","volume":"47","author":"SI Motegi","year":"2020","unstructured":"Motegi SI, Sekiguchi A, Ikeuchi H, Sakairi T, Ogawa H, Fujii T, Sohda M, Yajima T, Ida S, Takayasu Y, Shimoda Y, Hiromura K, Saeki H, Shirabe K, Chikamatsu K, Yokoo H, Oyama T, Ishikawa O (2020) Clinical features of anti-transcription intermediary factor 1gamma (TIF1gamma)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1gamma expression in tumors in the pathogenesis of cancer-associated dermatomyositis. J Dermatol 47(12):1395\u20131402","journal-title":"J Dermatol"},{"issue":"2","key":"8944_CR49","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","volume":"57","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Martinez MA, Milisenda JC, Aparicio-Espanol G, Labrador-Horrillo M, Garcia-Patos V, Grau-Junyent JM, Selva-O\u2019Callaghan A (2018) Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford) 57(2):388\u2013396","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"8944_CR50","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1093\/rheumatology\/keab260","volume":"60","author":"N Cordel","year":"2021","unstructured":"Cordel N, Derambure C, Coutant S, Mariette X, Jullien D, Debarbieux S, Chosidow O, Meyer A, Bessis D, Joly P, Mathian A, Levesque H, Sabourin JC, Tournier I, Boyer O, OncoMyositis Study group (2021) TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1gamma positive cancer-associated dermatomyositis. Rheumatology (Oxford) 60(12):5863\u20135867","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"8944_CR51","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/1346-8138.15284","volume":"47","author":"N Ikeda","year":"2020","unstructured":"Ikeda N, Yamaguchi Y, Kanaoka M, Ototake Y, Akita A, Watanabe T, Aihara M (2020) Clinical significance of serum levels of anti-transcriptional intermediary factor 1-gamma antibody in patients with dermatomyositis. J Dermatol 47(5):490\u2013496","journal-title":"J Dermatol"},{"issue":"3","key":"8944_CR52","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1074\/mcp.RA119.001905","volume":"19","author":"J Pan","year":"2020","unstructured":"Pan J, Yu L, Wu Q, Lin X, Liu S, Hu S, Rosa C, Eichinger D, Pino I, Zhu H, Qian J, Huang Y (2020) Integration of IgA and IgG autoantigens improves performance of biomarker panels for early diagnosis of lung cancer. Mol Cell Proteomics 19(3):490\u2013500","journal-title":"Mol Cell Proteomics"},{"issue":"17","key":"8944_CR53","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.7150\/ijms.50169","volume":"17","author":"M Chen","year":"2020","unstructured":"Chen M, Lin X, Zhang L, Yu L, Wu Q, Zhang S, Xue F, Huang Y (2020) Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer. Int J Med Sci 17(17):2744\u20132750","journal-title":"Int J Med Sci"},{"issue":"4","key":"8944_CR54","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/acr.23325","volume":"70","author":"P Venalis","year":"2018","unstructured":"Venalis P, Selickaja S, Lundberg K, Rugiene R, Lundberg IE (2018) Association of anti-transcription intermediary factor 1gamma antibodies with paraneoplastic rheumatic syndromes other than dermatomyositis. Arthritis Care Res (Hoboken) 70(4):648\u2013651","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"8944_CR55","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/08923973.2021.1910833","volume":"43","author":"M Vazquez-Del Mercado","year":"2021","unstructured":"Vazquez-Del Mercado M, Martinez-Garcia EA, Daneri-Navarro A, Gomez-Banuelos E, Martin-Marquez BT, Pizano-Martinez O, Wilson-Manriquez EA, Corona-Sanchez EG, Chavarria-Avila E, Sandoval-Garcia F, Satoh M (2021) Presence of anti-TIF-1gamma, anti-Ro52, anti-SSA\/Ro60 and anti-Su\/Ago2 antibodies in breast cancer: a cross-sectional study. Immunopharmacol Immunotoxicol 43(3):328\u2013333","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"9","key":"8944_CR56","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/rheumatology\/kew215","volume":"55","author":"EH Kang","year":"2016","unstructured":"Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW (2016) Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford) 55(9):1631\u20131641","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"8944_CR57","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/art.38093","volume":"65","author":"DF Fiorentino","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 65(11):2954\u20132962","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8944_CR58","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/rheumatology\/kez527","volume":"59","author":"K Oya","year":"2020","unstructured":"Oya K, Inoue S, Saito A, Nakamura Y, Ishitsuka Y, Fujisawa Y, Watanabe R, Taguchi S, Fujimoto M, Okiyama N (2020) Pregnancy triggers the onset of anti-transcriptional intermediary factor 1gamma antibody-positive dermatomyositis: a case series. Rheumatology (Oxford) 59(6):1450\u20131451","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"8944_CR59","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","volume":"60","author":"AGS Oldroyd","year":"2021","unstructured":"Oldroyd AGS, Allard AB, Callen JP, Chinoy H, Chung L, Fiorentino D, George MD, Gordon P, Kolstad K, Kurtzman DJB, Machado PM, McHugh NJ, Postolova A, Selva-O\u2019Callaghan A, Schmidt J, Tansley S, Vleugels RA, Werth VP, Aggarwal R (2021) A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford) 60(6):2615\u20132628","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"8944_CR60","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s10067-019-04562-w","volume":"38","author":"E Jia","year":"2019","unstructured":"Jia E, Wei J, Geng H, Qiu X, Xie J, Xiao Y, Zhong L, Xiao M, Zhang Y, Jiang Y, Zhang J (2019) Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review. Clin Rheumatol 38(8):2189\u20132193","journal-title":"Clin Rheumatol"},{"issue":"8","key":"8944_CR61","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/art.40895","volume":"71","author":"A Aussy","year":"2019","unstructured":"Aussy A, Freret M, Gallay L, Bessis D, Vincent T, Jullien D, Drouot L, Fabienne J, Joly P, Isabelle M, Meyer A, Sibilia J, Bader-Meunier B, Hachulla E, Hamidou M, Hue S, Charuel JL, Fabien N, Viailly PJ, Allenbach Y, Benveniste O, Cordel N, Boyer O, OncoMyositis Study Group (2019) The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. Arthritis Rheumatol 71(8):1360\u20131370","journal-title":"Arthritis Rheumatol"},{"key":"8944_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y (2020) Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res 8:49","journal-title":"Biomark Res"},{"issue":"6","key":"8944_CR63","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.amjmed.2009.11.012","volume":"123","author":"A Selva-O'Callaghan","year":"2010","unstructured":"Selva-O\u2019Callaghan A, Grau JM, Gamez-Cenzano C, Vidaller-Palacin A, Martinez-Gomez X, Trallero-Araguas E, Andia-Navarro E, Vilardell-Tarres M (2010) Conventional cancer screening versus PET\/CT in dermatomyositis\/polymyositis. Am J Med 123(6):558\u2013562","journal-title":"Am J Med"},{"issue":"4","key":"8944_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03707","volume":"6","author":"X Li","year":"2020","unstructured":"Li X, Tan H (2020) Value of (18)F-FDG PET\/CT in the detection of occult malignancy in patients with dermatomyositis. Heliyon 6(4):e03707","journal-title":"Heliyon"},{"issue":"1","key":"8944_CR65","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.semarthrit.2018.10.021","volume":"49","author":"A Kundrick","year":"2019","unstructured":"Kundrick A, Kirby J, Ba D, Leslie D, Olsen N, Foulke G (2019) Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. Semin Arthritis Rheum 49(1):140\u2013144","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"8944_CR66","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.rdc.2020.05.006","volume":"46","author":"S Moghadam-Kia","year":"2020","unstructured":"Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R (2020) Risk factors and cancer screening in myositis. Rheum Dis Clin North Am 46(3):565\u2013576","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"8944_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009639","volume":"97","author":"H Leatham","year":"2018","unstructured":"Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, Fiorentino D (2018) Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts. Medicine (Baltimore) 97(2):e9639","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"8944_CR68","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archderm.138.7.885","volume":"138","author":"A Sparsa","year":"2002","unstructured":"Sparsa A, Liozon E, Herrmann F, Ly K, Lebrun V, Soria P, Loustaud-Ratti V, Bouyssou-Gauthier ML, Boulinguez S, Bedane C, Jauberteau MO, Vidal E, Bonnetblanc JM (2002) Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 138(7):885\u2013890","journal-title":"Arch Dermatol"},{"issue":"5","key":"8944_CR69","doi-asserted-by":"publisher","first-page":"432","DOI":"10.21037\/atm-20-5215","volume":"9","author":"U Khanna","year":"2021","unstructured":"Khanna U, Galimberti F, Li Y, Fernandez AP (2021) Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening? Ann Transl Med 9(5):432","journal-title":"Ann Transl Med"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-022-08944-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T20:10:50Z","timestamp":1668888650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-022-08944-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8944"],"URL":"https:\/\/doi.org\/10.1007\/s12016-022-08944-y","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"11 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}